|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinicopathological differences and correlations between right and left colon cancer显示文摘BACKGROUND The differences in histopathology and molecular biology between right colon cancer(RCC)and left colon cancer(LCC)were first reported in the literature by Bufill in 1990.Since then,a large number of studies have confirmed their differences in epidemiology,clinical presentation,comorbidities and biological behaviours,which may be related to the difference in prognosis and overall survival(OS)between the two groups.AIM To investigate statistically significant differences between Greek patients with LCC and RCC.METHODS The present observational study included 144 patients diagnosed with colon cancer of any stage who received chemotherapy in a Greek tertiary oncology hospital during a 2.5-year period.Clinical information,comorbidities,histopathologic characteristics and molecular biomarkers were collected from the patients’medical records retrospectively,while administered chemotherapy regimens,targeted agents,progression-free survival(PFS)periods with first-and second-line chemotherapy and OS were recorded retroactively and prospectively.Data analysis was performed with the SPSS statistical package.RESULTS Eighty-six males and 58 females participated in the study.One hundred(69.4%)patients had a primary lesion in the left colon,and 44(30.6%)patients had a primary lesion in the right colon.Patients with RCC were more likely to display anaemia than patients with LCC[odds ratio(OR)=3.09],while LCC patients were more likely to develop rectal bleeding(OR=3.37)and a feeling of incomplete evacuation(OR=2.78)than RCC patients.Considering comorbidities,RCC patients were more likely to suffer from diabetes(OR=3.31)and coronary artery disease(P=0.056)than LCC patients.The mucinous differentiation rate was higher in the right-sided group than in the left-sided group(OR=4.49),as was the number of infiltrated lymph nodes(P=0.039),while the percentage of high-grade differentiation was higher in the group of patients with left-sided colon cancer than in RCC patients(OR=2.78).RAS wild-type patients who received anti-epidermal growth factor receptor(EGFR):Treatment experienced greater benefit(PFS:16.5 mo)than those who received anti-vascular endothelial growth factor treatment(PFS:13.7 mo)(P=0.05),while among RAS wild-type patients who received anti-EGFR treatment,LCC patients experienced greater benefit(PFS:15.8 mo)than the RCC subgroup(PFS:5.5 mo)in the first-line chemotherapy setting(P=0.034).BRAF-mutant patients had shorter PFS(9.3 mo)than BRAF wild-type patients(14.5 mo)(P=0.033).RCC patients showed a shorter tumour recurrence period(7.7 mo)than those with LCC(14.5 mo)(P<0.001),as well as shorter(OS)(58.4 mo for RCC patients;82.4 mo for LCC patients)(P=0.018).CONCLUSION RCC patients present more comorbidities,worse histological and molecular characteristics and a consequently higher probability of tumour recurrence,poor response to targeted therapy and shorter OS than LCC patients. | Ioannis Kalantzis Afroditi Nonni Kitty Pavlakis Eumorphia-Maria Delicha Konstantinos Miltiadou Christos Kosmas Nikolaos Ziras Konstantinos Gkoumas Harikleia Gakiopoulou | 2020 | World Journal of Clinical Cases2020，8，8： | 4 |
| 2 | ProANP and NT- proBNP levels to prospectively assess cardia- c function in breast cancer patients treated with cardiotoxic chemotherapy 显示文摘 | Kouloubinis A Kaklamanis L Ziras N | 2007 | Int J Cardio12007，122，3： | 1 |
| 3 | Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non - small cell lung cancer ( NSCLC ) : A multicemer phase Ⅱ study显示文摘 | Kakolyris S Ziras N Vamvakas L | 2006 | Lung Cancer2006，54，3： | 1 |
| 4 | A multieenter phase II tri- al of docetaxel and eapeeitabine as salvage treatment in anthracyeline- and taxane-pretreated patients with metastatic breast cancer 显示文摘 | Karaehaliou N Ziras N Syrigos K | 2012 | Cancer Chemother Pharmaeol2012，70，1： | 1 |
| 5 | Randomised phase-II trial of CAPIRI(capecitabine,irinotecan)plus bevacizumab vs FOLFIRI(folinic acid,5-fluorouracil,irinotecan)plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer(mCRC)显示文摘 | Souglakos J Ziras N Kakolyris S | 2012 | Br J Cancer2012，106，45： | 1 |
| 6 | 1H NMR-Based metabonomics approach in a rat model of acute liver injury and regeneration induced by CCl4administration显示文摘 | Zira A Kostidis S Theocharis S Sigala F Engelsen SB Andreadou I | 2013 | Toxicology2013，303，： | 1 |
| 7 | Phase Ⅰ study of postoperative radiotherapy with concomitant weekly irinotecan,5-fluorouracil and folinic acid in locally advanced rectal cancer显示文摘 | Ziras N Tsoutsou P Koliarakis N | | 0，，： | 1 |
| 8 | Acute liver acetaminophen toxicity in rabbits and the use of antidotes:a metabonomic approach in serum显示文摘 | Zira A Mikros E Giannioti K | 2009 | J Appl Toxicol2009，29，5： | 1 |
| 9 | Randomised phase-Ⅱ trial of CAPIRI(capecitabine,irinotecan)plus bevacizumab vs FOLFIRI(folinic acid,5-fluorouracil,irinotecan)plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer(mCRC)显示文摘 | SOUGLAKOS J ZIRAS N KAKOLYRIS S | 2012 | Br J Cancer2012，106，3： | 1 |
| 10 | Multicenter phase Ⅱ study of gemcitabine and oxaliplatin (GEMOX) as secondline chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan显示文摘 | Ziras N Potamianou A Varthalitis I | 2006 | Oncology2006，70，2： | 1 |
| 11 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline-and taxane-pretreated patients with metastatic breast cancer显示文摘 | Karachaliou N Ziras N Syrigos K | 2012 | Cancer Chemother Pharmacol2012，70，1： | 1 |
| 12 | 1 H NMR-based metabonomics approach in a rat model of acute liver injury and regeneration induced by CCl 4 administration 显示文摘 | Zira A Kostidis S Theocharis S | 2013 | Toxicology2013，303，： | 1 |
| 13 | A multieenter phase Ⅱ trial of doeetaxel and eapecitabine as salvage treatment in anthracyeline-and taxane-pretreated patients with metastatic breast eaneer显示文摘 | Karachaliou N Ziras N Syrigos K | 2012 | Caneer Chemother Pharmaeol2012，70，1： | 1 |
| 14 | 1H NMR-based metabonomics approach in a rat model of acute liver injury and regeneration induced by CCl4 administration显示文摘 | Zira A Kostidis S Theocharis S | | 0，，： | 1 |
| 15 | Front - line treatment of advanced breast cancer with docetaxel and epirubicin: a muhicenter phase II study 显示文摘 | Mavroudis D Alexopoulos A Ziras N | 2000 | Ann Oncol2000，11，10： | 1 |
| 16 | , Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma? 显示文摘 | Kouraklis G Zira A Tsourouflis G | 2009 | Digestive Diseases and Sciences2009，54，5： | 1 |
| 17 | Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase Ⅱ study显示文摘 | Kakolyris S Ziras N Vamvakas L | 2006 | Lung Cancer2006，54，3： | 1 |
| 18 | A muhicenter phase II trial of docetaxel and capecitabine as salvage treatment in an- thracycline- and taxane-pretreated patients with metastatic breast cancer 显示文摘 | Karachaliou N Ziras N Syrigos K | 2012 | Cancer Chemother Pharmacol2012，70，： | 1 |
| 19 | Randomised phase-Ⅱ trial of CAPIRI (capecitabine,irinotecan) plus bevacizumab vs FOLFIRI (folinic acid,5-fluorouracil,irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)显示文摘 | Souglakos J Ziras N Kakolyris S | 2012 | Br J Cancer2012，106，3： | 1 |
| 20 | Clinical implication of plasma neutrophilgelatinase-associated lipocalin (NGAL) concentrations in patients withadvanced carotid atherosclerosis 显示文摘 | Giaginis C Zira A Katsargyris A | 2010 | Clin Chem Lab Med2010，48，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员